Powdered phosphate lowering medicine for Indian patients on hemodialysis.
Phase 3
Completed
- Conditions
- Health Condition 1: null- CHRONIC RENAL FAILURE ON MAINTENANCE HEMODIALYSIS
- Registration Number
- CTRI/2015/11/006342
- Lead Sponsor
- emcure pharmaceuticals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Patients with the diagnosis of chronic renal disease undergoing hemodialysis for at least 6 weeks
Exclusion Criteria
Hypercalcaemia, Significant gastrointestinal disorder (including known active peptic ulcer, Crohnâ??s disease, ulcerative colitis, irritable bowel syndrome, GI motility disorder),Current malignancy, Pregnant and lactating women, Known hypersensitivity to phosphate binders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OWERING IN SERUM PHOSPHORUSTimepoint: 0 week, 4 week, 5 week, 9 week
- Secondary Outcome Measures
Name Time Method REDUCTION IN LOW DENSITY LIPOPROTEIN, TRIGLYCERIDE, TOTAL CHOLESTROL AND C-REACTIVE PROTEINTimepoint: 0 WEEK, 4 WEEK, 5 WEEK, 9 WEEK